ID
14000
Description
Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT02511184
Link
https://clinicaltrials.gov/show/NCT02511184
Keywords
Versions (1)
- 3/21/16 3/21/16 -
Uploaded on
March 21, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility ALK-positive Advanced NSCLC NCT02511184
Eligibility ALK-positive Advanced NSCLC NCT02511184
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
ALK receptor tyrosine kinase assay
Data type
boolean
Alias
- UMLS CUI [1]
- C3203742
Description
Immunologic Deficiency Syndromes
Data type
boolean
Alias
- UMLS CUI [1]
- C0021051
- UMLS CUI [2]
- C4039704
Description
Autoimmune Diseases
Data type
boolean
Alias
- UMLS CUI [1]
- C0004364
Description
Lung Diseases
Data type
boolean
Alias
- UMLS CUI [1]
- C0206062
Similar models
Eligibility ALK-positive Advanced NSCLC NCT02511184
- StudyEvent: Eligibility
C0007131 (UMLS CUI [1,2])
C4039704 (UMLS CUI [2])